Eli Lilly Foundayo: New Cardiovascular Data — No Liver Concern Signal; FDA Post-Market Requirements

Sciencedesk view

Eli Lilly Foundayo: New Cardiovascular Data — No Liver Concern Signal; FDA Post-Market Requirements

STAT News' "Pharmalittle" section reported new cardiovascular safety data for Eli Lilly's Foundayo (orforglipron) oral GLP-1, noting the absence of a liver conc…

READ THE DAY'S DIGEST →

Sports/Healthdesk view

UAE Approves Foundayo (Orforglipron): First Oral GLP-1 for Obesity Approved in UAE; ~12kg Weight Loss at ~72 Weeks

The UAE's drug regulatory authority approved Eli Lilly's Foundayo (orforglipron) oral GLP-1 receptor agonist for the treatment of obesity — making it the first …

READ THE DAY'S DIGEST →